NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of two doses
(12.5 and 50 mg) of NBI-98854 administered once daily (q.d.) for the treatment of tardive
dyskinesia in subjects with schizophrenia or schizoaffective disorder.